PRN2246: BTK Inhibitor
CNS and Autoimmune Diseases

IND-Enabling Phase

Bruton’s tyrosine kinase (BTK) is a key element in the B-cell signaling pathway. The role of B-cells in autoimmunity has been clinically validated with B-cell depleting therapy including diseases that affect the nervous system like Neuromyelitis Optica and Multiple Sclerosis. The development of an orally available therapy that could penetrate the Central Nervous System in order to effectively and safely modulate B-cell function without depleting B-cells could be a significant advance in the treatment of these diseases.

  • Ongoing IND enabling studies of an oral BTK inhibitor which combines an excellent selectivity profile and pharmacokinetic properties to achieve efficacy at very low doses

  • BTK inhibition impacts multiple immune cell signaling pathways relevant in both the periphery and within the CNS, holding promise for the treatment of neurologic diseases including multiple sclerosis

  • Distinct from other BTK inhibitors, PRN2246 readily permeates the blood brain barrier (BBB)

  • BTK modulates immune cell signaling central to many components of autoimmune and inflammatory diseases